These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 12846942)

  • 21. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome.
    Creed F; Fernandes L; Guthrie E; Palmer S; Ratcliffe J; Read N; Rigby C; Thompson D; Tomenson B;
    Gastroenterology; 2003 Feb; 124(2):303-17. PubMed ID: 12557136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome.
    Niedzielin K; Kordecki H; Birkenfeld B
    Eur J Gastroenterol Hepatol; 2001 Oct; 13(10):1143-7. PubMed ID: 11711768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.
    Lembo T; Wright RA; Bagby B; Decker C; Gordon S; Jhingran P; Carter E;
    Am J Gastroenterol; 2001 Sep; 96(9):2662-70. PubMed ID: 11569692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.
    Müller-Lissner SA; Fumagalli I; Bardhan KD; Pace F; Pecher E; Nault B; Rüegg P
    Aliment Pharmacol Ther; 2001 Oct; 15(10):1655-66. PubMed ID: 11564007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.
    Camilleri M; Chey WY; Mayer EA; Northcutt AR; Heath A; Dukes GE; McSorley D; Mangel AM
    Arch Intern Med; 2001 Jul; 161(14):1733-40. PubMed ID: 11485506
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Irritable bowel syndrome: is the search for lactose intolerance justified?
    Parker TJ; Woolner JT; Prevost AT; Tuffnell Q; Shorthouse M; Hunter JO
    Eur J Gastroenterol Hepatol; 2001 Mar; 13(3):219-25. PubMed ID: 11293439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome.
    Poynard T; Regimbeau C; Benhamou Y
    Aliment Pharmacol Ther; 2001 Mar; 15(3):355-61. PubMed ID: 11207510
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: tegaserod.
    Camilleri M
    Aliment Pharmacol Ther; 2001 Mar; 15(3):277-89. PubMed ID: 11207504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome.
    Jones J; Boorman J; Cann P; Forbes A; Gomborone J; Heaton K; Hungin P; Kumar D; Libby G; Spiller R; Read N; Silk D; Whorwell P
    Gut; 2000 Nov; 47 Suppl 2(Suppl 2):ii1-19. PubMed ID: 11053260
    [No Abstract]   [Full Text] [Related]  

  • 30. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials.
    Jailwala J; Imperiale TF; Kroenke K
    Ann Intern Med; 2000 Jul; 133(2):136-47. PubMed ID: 10896640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome.
    Nobaek S; Johansson ML; Molin G; Ahrné S; Jeppsson B
    Am J Gastroenterol; 2000 May; 95(5):1231-8. PubMed ID: 10811333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome.
    Prather CM; Camilleri M; Zinsmeister AR; McKinzie S; Thomforde G
    Gastroenterology; 2000 Mar; 118(3):463-8. PubMed ID: 10702196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral.
    Thompson WG; Heaton KW; Smyth GT; Smyth C
    Gut; 2000 Jan; 46(1):78-82. PubMed ID: 10601059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Division of the irritable bowel syndrome into subgroups on the basis of daily recorded symptoms in two outpatients samples.
    Ragnarsson G; Bodemar G
    Scand J Gastroenterol; 1999 Oct; 34(10):993-1000. PubMed ID: 10563669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome.
    Vanner SJ; Depew WT; Paterson WG; DaCosta LR; Groll AG; Simon JB; Djurfeldt M
    Am J Gastroenterol; 1999 Oct; 94(10):2912-7. PubMed ID: 10520844
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Functional bowel disorders and functional abdominal pain.
    Thompson WG; Longstreth GF; Drossman DA; Heaton KW; Irvine EJ; Müller-Lissner SA
    Gut; 1999 Sep; 45 Suppl 2(Suppl 2):II43-7. PubMed ID: 10457044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome.
    Bennett EJ; Tennant CC; Piesse C; Badcock CA; Kellow JE
    Gut; 1998 Aug; 43(2):256-61. PubMed ID: 10189854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abnormal colonic fermentation in irritable bowel syndrome.
    King TS; Elia M; Hunter JO
    Lancet; 1998 Oct; 352(9135):1187-9. PubMed ID: 9777836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.
    Mohammad S; Zhou Z; Gong Q; January CT
    Am J Physiol; 1997 Nov; 273(5):H2534-8. PubMed ID: 9374794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sexual abuse is more frequently reported by IBS patients than by patients with organic digestive diseases or controls. Results of a multicentre inquiry. French Club of Digestive Motility.
    Delvaux M; Denis P; Allemand H
    Eur J Gastroenterol Hepatol; 1997 Apr; 9(4):345-52. PubMed ID: 9160196
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.